
TY  - JOUR
TI  - POSTER PRESENTATION ABSTRACTS
JO  - HPB
VL  - 13
IS  - s3
SN  - 1365-182X
UR  - https://doi.org/10.1111/j.1477-2574.2011.00386.x
DO  - doi:10.1111/j.1477-2574.2011.00386.x
SP  - 174
EP  - 244
PY  - 2011
ER  - 

TY  - JOUR
TI  - Molecular biology of muscle development
JO  - Journal of Cellular Biochemistry
JA  - J. Cell. Biochem.
VL  - 56
IS  - S18D
SN  - 0730-2312
UR  - https://doi.org/10.1002/jcb.240560810
DO  - doi:10.1002/jcb.240560810
SP  - 461
EP  - 541
PY  - 1994
ER  - 

TY  - JOUR
AU  - Wang, Wei
AU  - Qin, Jiang-Jiang
AU  - Rajaei, Mehrdad
AU  - Li, Xin
AU  - Yu, Xiaoyi
AU  - Hunt, Courtney
AU  - Zhang, Ruiwen
TI  - Targeting MDM2 for novel molecular therapy: Beyond oncology
JO  - Medicinal Research Reviews
JA  - Med Res Rev
VL  - n/a
IS  - n/a
SN  - 0198-6325
UR  - https://doi.org/10.1002/med.21637
DO  - doi:10.1002/med.21637
KW  - dementia
KW  - diabetes
KW  - inflammation
KW  - MDM2
KW  - noncarcinogenic
KW  - p53
AB  - Abstract The murine double minute 2 (MDM2) oncogene exerts major oncogenic activities in human cancers; it is not only the best-documented negative regulator of the p53 tumor suppressor, but also exerts p53-independent activities. There is an increasing interest in developing MDM2-based targeted therapies. Several classes of MDM2 inhibitors have been evaluated in preclinical models, with a few entering clinical trials, mainly for cancer therapy. However, noncarcinogenic roles for MDM2 have also been identified, demonstrating that MDM2 is involved in many chronic diseases and conditions such as inflammation and autoimmune diseases, dementia and neurodegenerative diseases, heart failure and cardiovascular diseases, nephropathy, diabetes, obesity, and sterility. MDM2 inhibitors have been shown to have promising therapeutic efficacy for treating inflammation and other nonmalignant diseases in preclinical evaluations. Therefore, targeting MDM2 may represent a promising approach for treating and preventing these nonmalignant diseases. In addition, a better understanding of how MDM2 works in nonmalignant diseases may provide new biomarkers for their diagnosis, prognostic prediction, and monitoring of therapeutic outcome. In this review article, we pay special attention to the recent findings related to the roles of MDM2 in the pathogenesis of several nonmalignant diseases, the therapeutic potential of its downregulation or inhibition, and its use as a biomarker.
ER  - 

AU  - Perrucci, Gianluca L
AU  - Zanobini, Marco
AU  - Gripari, Paola
AU  - Songia, Paola
AU  - Alshaikh, Bayan
AU  - Tremoli, Elena
AU  - Poggio, Paolo
C7  - pp. 799-818
TI  - Pathophysiology of Aortic Stenosis and Mitral Regurgitation
UR  - https://doi.org/10.1002/cphy.c160020
DO  - doi:10.1002/cphy.c160020
SP  - 799-818
AB  - ABSTRACT The global impact of the spectrum of valve diseases is a crucial, fast-growing, and underrecognized health problem. The most prevalent valve diseases, requiring surgical intervention, are represented by calcific and degenerative processes occurring in heart valves, in particular, aortic and mitral valve. Due to the increasing elderly population, these pathologies will gain weight in the global health burden. The two most common valve diseases are aortic valve stenosis (AVS) and mitral valve regurgitation (MR). AVS is the most commonly encountered valve disease nowadays and affects almost 5% of elderly population. In particular, AVS poses a great challenge due to the multiple comorbidities and frailty of this patient subset. MR is also a common valve pathology and has an estimated prevalence of 3% in the general population, affecting more than 176 million people worldwide. This review will focus on pathophysiological changes in both these valve diseases, starting from the description of the anatomical aspects of normal valve, highlighting all the main cellular and molecular features involved in the pathological progression and cardiac consequences. This review also evaluates the main approaches in clinical management of these valve diseases, taking into account of the main published clinical guidelines. ? 2017 American Physiological Society. Compr Physiol 7:799-818, 2017.
ER  - 

TY  - JOUR
TI  - POSTER PRESENTATION
JO  - Respirology
JA  - Respirology
VL  - 21
IS  - S3
UR  - https://doi.org/10.1111/resp.12939_15
DO  - doi:10.1111/resp.12939_15
SP  - 80
EP  - 213
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts—Posters
JO  - Alcoholism: Clinical and Experimental Research
VL  - 36
IS  - s1
UR  - https://doi.org/10.1111/j.1530-0277.2012.01803.x
DO  - doi:10.1111/j.1530-0277.2012.01803.x
SP  - 11A
EP  - 303A
PY  - 2012
ER  - 

TY  - JOUR
TI  - Glasgow Pathology 2007. 4th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain and Ireland. 3–6 July 2007. Hosted by the Department of Pathology, University of Glasgow.
JO  - The Journal of Pathology
JA  - J. Pathol.
VL  - 213
IS  - S1
UR  - https://doi.org/10.1002/path.2255
DO  - doi:10.1002/path.2255
SP  - 1A
EP  - 65A
PY  - 2007
ER  - 

TY  - JOUR
TI  - 2019 ACPGBI Poster Abstracts
JO  - Colorectal Disease
JA  - Colorectal Dis
VL  - 21
IS  - S2
UR  - https://doi.org/10.1111/codi.14770
DO  - doi:10.1111/codi.14770
SP  - 10
EP  - 59
PY  - 2019
ER  - 

TY  - JOUR
TI  - Abstracts of the 76th Annual Meeting of the Japanese Cancer Association; 2017 Sept 28-30; Yokohama, Japan
JO  - Cancer Science
JA  - Cancer Sci
VL  - 109
IS  - S1
UR  - https://doi.org/10.1111/cas.13499
DO  - doi:10.1111/cas.13499
SP  - 1
EP  - 1325
PY  - 2018
ER  - 

C7  - pp. 1029-1074
TI  - Index
SN  - 9781118486177
UR  - https://doi.org/10.1002/9781118486160.index
DO  - doi:10.1002/9781118486160.index
SP  - 1029-1074
PY  - 2018
ER  - 

TY  - JOUR
TI  - Solving Clinical Problems with Anatomical Solutions
JO  - Journal of Anatomy
JA  - J. Anat.
VL  - 232
IS  - 6
SN  - 9781118486177
UR  - https://doi.org/10.1111/joa.12806
DO  - doi:10.1111/joa.12806
SP  - 1038
EP  - 1064
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Gynecological Cancer
VL  - 14
IS  - s1
SN  - 9781118486177
UR  - https://doi.org/10.1111/j.1525-1438.2004.1315431.x
DO  - doi:10.1111/j.1525-1438.2004.1315431.x
SP  - 1
EP  - 249
PY  - 2004
ER  - 

TY  - JOUR
TI  - Oral presentations
JO  - Clinical Microbiology and Infection
VL  - 15
IS  - s4
SN  - 9781118486177
UR  - https://doi.org/10.1111/j.1469-0691.2009.02857.x
DO  - doi:10.1111/j.1469-0691.2009.02857.x
SP  - S1
EP  - S106
PY  - 2009
ER  - 

TY  - JOUR
TI  - American Society of Transplant Surgeons: 19th Annual State of the Art Winter Symposium
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 19
IS  - S1
SN  - 9781118486177
UR  - https://doi.org/10.1111/ajt.15186
DO  - doi:10.1111/ajt.15186
SP  - 13
EP  - 97
PY  - 2019
ER  - 

TY  - JOUR
TI  - Oral Presentations
JO  - Mycoses
JA  - Mycoses
VL  - 58
IS  - S3
SN  - 9781118486177
UR  - https://doi.org/10.1111/myc.12361
DO  - doi:10.1111/myc.12361
SP  - 2
EP  - 39
PY  - 2015
ER  - 

TY  - JOUR
TI  - Abstracts Oral
JO  - American Journal of Transplantation
VL  - 8
IS  - s2
SN  - 9781118486177
UR  - https://doi.org/10.1111/j.1600-6143.2008.02254.x
DO  - doi:10.1111/j.1600-6143.2008.02254.x
SP  - 177
EP  - 336
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts—Posters
JO  - Alcoholism: Clinical and Experimental Research
JA  - Alcohol Clin Exp Re
VL  - 43
IS  - S1
SN  - 9781118486177
UR  - https://doi.org/10.1111/acer.14059
DO  - doi:10.1111/acer.14059
SP  - 27A
EP  - 258A
PY  - 2019
ER  - 

C7  - pp. 842-873
TI  - Index
SN  - 9781405199438
UR  - https://doi.org/10.1002/9781118399668.index
DO  - doi:10.1002/9781118399668.index
SP  - 842-873
PY  - 2019
ER  - 

TY  - JOUR
TI  - Oral Presentations
JO  - Journal of Digestive Diseases
JA  - Journal of Digestive Diseases
VL  - 19
IS  - S1
SN  - 9781405199438
UR  - https://doi.org/10.1111/1751-2980.12663
DO  - doi:10.1111/1751-2980.12663
SP  - 3
EP  - 11
PY  - 2018
ER  - 

TY  - JOUR
TI  - Poster Sessions
JO  - BJU International
VL  - 109
IS  - s7
SN  - 9781405199438
UR  - https://doi.org/10.1111/j.1464-410X.2012.11177.x
DO  - doi:10.1111/j.1464-410X.2012.11177.x
SP  - 14
EP  - 56
PY  - 2012
ER  - 
